Mankind Pharma IPO Review
Mankind Pharma IPO is yet to receive analyst coverage — analyst reports and verdicts will be updated here as and when they are published. The IPO is priced in the band of ₹1026-1080 per share with a minimum lot size of 13 shares (minimum investment of ₹14,040). Subscription ran from 25 Apr 2023 to 27 Apr 2023. The issue size is ₹4,326 crore, entirely an offer for sale — the company receives none of the proceeds. In the meantime, you can track the live GMP and subscription status for early market signals.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Detailed review
Download our Android App to check other reviews.
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Mankind Pharma IPO?
Analyst coverage for Mankind Pharma IPO has not been published yet. Verdicts will be added here as analyst reports come in. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of N/A mean for Mankind Pharma IPO?
Analyst scoring is not yet available for Mankind Pharma IPO. The score will be updated once analyst reports start coming in.
What was the actual listing price of Mankind Pharma IPO?
Mankind Pharma IPO listed on May 9, 2023 at ₹1300, against the issue price of ₹1080 — a gain of +20.37% (₹220 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Mankind Pharma IPO?
Mankind Pharma IPO was priced at ₹1026-1080 per share. The minimum lot size is 13 shares, making the minimum investment approximately ₹14,040 at the upper end of the price band. Subscription ran from 25 Apr 2023 to 27 Apr 2023.
Explore Mankind Pharma IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
